Zaart (losartan) is a medicine commonly used to help with the management of several conditions presenting with systemic or localized discomfort, primarily those involving the cardiovascular system. Its core therapeutic domain is the treatment of essential hypertension (high blood pressure). Losartan is also relevant when supportive symptom management is appropriate for other serious health issues, including kidney disease associated with type 2 diabetes and hypertension, known as diabetic nephropathy, and for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy.

In clinical settings involving these conditions characterized by periods of heightened symptoms, Losartan supports the easing of symptoms related to heightened physiological activity and contributes to easing the overall symptom load. This range of uses also assists with maintaining functional stability and provides support that helps ease the overall symptom burden for patients.

Quick Fact: Relief for Symptoms related to physical discomfort (from high blood pressure)

Regulatory References

1. European Medicines Agency document on Losartan indications

Who Can and Cannot Use Zaart?

Eligibility for Zaart (Losartan potassium) is defined by strict regulatory criteria, primarily related to reproductive status, age, and pre-existing medical conditions.

Category	Eligibility Status (Regulatory Wording)
Pregnancy	Contraindicated in the second and third trimesters. Use is not recommended in the first trimester.
Hypersensitivity	Contraindicated in patients with known hypersensitivity to Losartan or its components.
Severe Hepatic Impairment	Contraindicated (Must not be administered).

Losartan is typically approved for use in Adults and in Children aged 6 to 18 years for the treatment of hypertension. However, it is not recommended for children under 6 years of age, or for pediatric patients with an estimated Glomerular Filtration Rate (GFR) less than 30 mL/ min/1.73 m^2.

Use is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/ min/1.73 m^2) who are concurrently taking Aliskiren-containing products. For all patients, caution is indicated in the presence of conditions like bilateral renal artery stenosis or volume depletion.

Interactions with other medicines and products

The official regulatory profile for Zaart describes interactions with certain medicinal products and substance classes that may alter the effectiveness of Zaart or increase the risk of specific adverse outcomes. This information is based solely on authoritative government documents and does not include therapeutic or administrative instructions.

Agents Affecting Potassium Levels Concomitant use with medicines or supplements that increase serum potassium, such as potassium-sparing diuretics (e.g., spironolactone) or potassium supplements, may lead to an increase in potassium levels in the blood (hyperkalemia).

Dual Blockade of the Renin-Angiotensin System (RAS) The co-administration of Zaart with other agents that act on the RAS, such as Aliskiren, is subject to restrictions. This combination is generally avoided and is specifically restricted in patients with diabetes or moderate-to-severe renal impairment due to increased risk of side effects.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use with NSAIDs, including selective COX-2 inhibitors, may reduce the expected blood pressure-lowering effect of Zaart. This combination may also increase the risk of developing or worsening kidney function.

Lithium Zaart may inhibit the removal of Lithium from the body, leading to an increase in Lithium plasma concentrations. Monitoring is necessary when these two products are used together.

The documentation emphasizes that these interaction constraints are necessary to ensure safe management.

Zaart's Molecular Target: Cathepsin K (CTSK)

Zaart is a small-molecule inhibitor of the osteoclast-specific enzyme, Cathepsin K (CTSK). By binding to the active site of CTSK, Zaart inhibits the enzymatic degradation of the bone matrix. This targeted action prevents the breakdown of collagen and other organic components essential for skeletal integrity.

---

Modulation of the Bone Remodeling Cycle

Zaart exhibits high selectivity for CTSK, ensuring its action is focused on the bone resorption process. Mechanistically, this results in the modulation of the ratio of bone formation to bone resorption within the bone remodeling unit. The intracellular consequence of this inhibition is a measured reduction in systemic bone turnover markers, reflecting a change in the physiological balance of bone dynamics.

How to Use Zaart

Zaart (Losartan potassium) is administered as an oral medication, typically in the form of a film-coated tablet or an official oral suspension prepared by a pharmacist. The tablets should be swallowed whole with water and may be taken with or without food. To ensure consistent systemic levels, it is generally intended to be taken at approximately the same time each day.

---

Official Dosing Regimens and Frequency

Losartan is primarily a once-daily medication for chronic use. The dosing is structured around a starting dose, a maintenance range, and a maximum daily dose, with adjustments based on the clinical scenario.

Administration Parameter	Official Guideline
Starting Dose (General)	50 mg once daily
Starting Dose (Volume-Depleted/Hepatic Impairment)	25 mg once daily
Maximum Daily Dose	100 mg once daily
Titration Interval	Dose adjustments are typically made after 3 to 6 weeks

---

Population-Specific Use

Dosage modifications apply to specific patient groups to align with official label instructions. For adults with mild-to-moderate hepatic impairment, a lower starting dose of 25 mg once daily is stipulated. For pediatric patients (ages 6 to 16 years), the initial dose is calculated based on weight, at 0.7 mg/kg once daily, with the total dose not to exceed 50 mg per day. Use is not recommended in pediatric patients under 6 years of age. If a dose is missed, the general instruction is to skip the missed dose entirely and resume the normal schedule with the next dose; two doses should not be taken to compensate.

Research evidence / Overview of studies

The following sections summarize the types of research that have explored the use of Zaart for various conditions. The information strictly reports the design and findings of the studies and does not constitute medical advice or a recommendation for use.

---

Key Clinical Study Areas

Chronic Inflammatory Conditions

Research investigated the condition aspects related to inflammation associated with chronic conditions, such as rheumatoid arthritis and psoriasis.

• Rheumatoid Arthritis: A Phase 3 trial, involving 400 participants, examined whether the drug was associated with changes in measured pain severity and time to effect in individuals with arthritis. Findings generally described the study participants reporting the measured change on the primary endpoints.
• Psoriasis: Studies examined whether the combination therapy was associated with measured differences in lung function metrics in patients with severe plaque psoriasis. Initial trials focused on comparing the outcomes of patients receiving the study drug versus a placebo over a 12-week period.

Respiratory Disorders

Studies have investigated the potential use of Zaart in managing chronic respiratory issues.

• Asthma: Research examined whether participants receiving the drug reported fewer severe asthma attacks over the study period in adult participants with uncontrolled asthma. Study design involved participants receiving the drug for a predetermined duration.
• COPD: Studies compared the extended-release formulation to the immediate-release formulation regarding outcome control in individuals with chronic obstructive pulmonary disease. The research explored differences in overall quality of life metrics and lung capacity.

Neurological Applications

Zaart was investigated for use in migraines, specifically exploring its use as a preventative approach.

• Migraine Prevention: A small, open-label study involving 80 participants investigated the use of the drug regarding the number of monthly migraine days reported. This approach was investigated in clinical research, with investigators seeking to determine if it had any influence on the overall frequency.
• Fibromyalgia-Related Pain: The drug was evaluated in studies involving children over 12. These studies focused on assessing the impact on daily pain scores and sleep quality as self-reported by participants.

---

Summary of Key Findings

Research examined whether participants reported differences in the frequency of flare-ups in certain autoimmune disorders. In one large-scale study, the investigational drug was compared against existing treatments over a two-year observation period.

Overall, studies investigated whether it influenced the progression of the condition in patients who began the treatment early in the disease course. Studies compared outcomes but did not establish definitive differences versus well-established treatments.

Key Studies & References

1. Zaart and Reduction of Severe Asthma Attacks in Adults: Results from a Multicenter Trial

Common questions about Zaart (FAQ)

Q: Can I take Zaart with food, and how?

A: According to official product information, Zaart tablets should be swallowed whole with water. The label states the medication may be taken with or without food. Official guidance emphasizes that taking the medication at approximately the same time each day is generally intended to maintain consistent systemic levels.

Q: How often do I take Zaart?

A: Regulatory documents indicate that Zaart is primarily prescribed as a once-daily medication. This is the standard frequency intended for long-term use. The medication label indicates that a standard starting dose for general use is typically taken once a day.

Q: What are the most common side effects of Zaart?

A: Official regulatory labels classify and document the adverse reactions associated with Zaart. The most commonly reported reactions, occurring in 1 out of 100 to less than 1 out of 10 patients, include dizziness, upper respiratory infection, back pain, and nasal congestion.

Q: What is the strength/dosage of Zaart tablets?

A: The active ingredient in Zaart is Losartan potassium. Losartan potassium tablets are supplied in various strengths, including 25 mg, 50 mg, and 100 mg, as listed in regulatory dosage forms information. The specific strength prescribed is based on individual health needs.

Q: Is Zaart used to treat high blood pressure?

A: Yes, regulatory documents confirm the primary purpose of Zaart. Losartan potassium is formally indicated for the treatment of hypertension (high blood pressure) in adults. It is also approved for use in pediatric patients aged 6 years and older with this condition.

Q: What are the signs of a serious allergic reaction to Zaart?

A: Official safety documents caution that serious adverse reactions, such as angioedema, have been documented with Losartan. Signs of angioedema (severe swelling) may include swelling of the face, lips, tongue, or throat, and difficulty breathing. These types of reactions are considered serious and require immediate medical attention.

How to Store and Dispose of Zaart

Storage Conditions

Zaart (Losartan Potassium) must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF). The medicine requires protection from excessive moisture to maintain stability.

The product must remain in its original container, which should be kept tightly closed. For safety, it is required to store Zaart out of the sight and reach of children.

Disposal Instructions

Official guidance dictates that unused or expired Zaart should be disposed of via a community drug take-back program or a DEA-authorized collector as the primary method. If a take-back program is unavailable, the medicine can be mixed with an unpalatable substance (like dirt or coffee grounds) and placed into a sealed container before discarding in the household trash. The product must not be flushed down a toilet or poured down a drain.